ホーム>>Infectious Disease>> Bacterial Diseases>> Tuberculosis>>Napyradiomycin A1

Napyradiomycin A1

カタログ番号GC47747

ナピラジオマイシン A1 は、ナピラジオマイシンのエナンチオ選択的化合物の 1 つです。

Products are for research use only. Not for human use. We do not sell to patients.

Napyradiomycin A1 化学構造

Cas No.: 103106-24-7

サイズ 価格 在庫数 個数
1 mg
$265.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Napyradiomycin A1 is a fungal metabolite originally isolated from C. rubra and has diverse biological activities.1,2 It is active against S. aureus, M. luteus, B. anthracis, C. bovis, and M. smegmatis (MICs = 1.56-12.5 µg/ml).1 Napyradiomycin A1 is an estrogen receptor antagonist (IC50 = 4.2 µM in rat uterine homogenates).2 It also inhibits mitochondrial NADH:ubiquinone oxidoreductase (complex I) and succinate:ubiquinone oxidoreductase (complex II) activities in bovine heart homogenates (IC50s = 20 and 9.7 µM, respectively).3

1.Shiomi, K., Iinuma, H., Hamada, M., et al.Novel antibiotics napyradiomycins. Production, isolation, physico-chemical properties and biological activityJ. Antibiot. (Tokyo)39(4)487-493(1986) 2.Hori, Y., Abe, Y., Shigematsu, N., et al.Napyradiomycins A and B1: Non-steroidal estrogen-receptor antagonists produced by a StreptomycesJ. Antibiot. (Tokyo)46(12)1890-1893(1993) 3.Yamamoto, K., Tashiro, E., Motohashi, K., et al.Napyradiomycin A1, an inhibitor of mitochondrial complexes I and IIJ. Antibiot. (Tokyo)65(4)211-214(2012)

レビュー

Review for Napyradiomycin A1

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Napyradiomycin A1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.